Source comparison
BPC-157 Capsules vs Injection Bioavailability — Absorption
Research from the University of Zagreb. Where BPC-157 was first isolated. Found that oral administration achieves approximately 15–30% of the systemic bioavailability of subcutaneous injection. The difference isn't marginal. Gastric acid denatures peptide bond
This comparison does not assign a generated winner or score.
- Research from the University of Zagreb. Where BPC-157 was first isolated. Found that oral administration achieves approximately 15–30% of the systemic bioavailability of subcutaneous injection. The difference isn't marginal. Gastric acid denatures peptide bonds within seconds of ingestion, breaking down the pentadecapeptide's structure before it can cross the intestinal barrier. Subcutaneous injection bypasses this entirely, delivering the intact peptide directly to systemic circulation.
- Our team has worked with research institutions testing both delivery methods across controlled conditions. The gap between capsule and injection outcomes comes down to three factors most comparisons overlook: proteolytic degradation in the stomach, hepatic first-pass metabolism, and absorption kinetics at the injection site.
- What is the bioavailability difference between BPC-157 capsules and injections?
- BPC-157 delivered subcutaneously achieves 85–95% systemic bioavailability, while oral capsules reach 15–30% due to gastric acid degradation and hepatic first-pass metabolism. Subcutaneous administration delivers the intact pentadecapeptide directly to circulation, bypassing enzymatic breakdown that destroys up to 85% of orally administered peptides. This difference directly impacts tissue concentration and therapeutic potential in research models.
- Yes, BPC-157 capsules versus injection bioavailability varies dramatically. But not because the peptide itself is different. The active compound is identical. The difference lies in what happens between administration and systemic absorption. Oral delivery exposes BPC-157 to gastric pepsin, pancreatic proteases, and hepatic cytochrome enzymes before a single molecule reaches target tissue. Injection avoids all three. This article covers the specific mechanisms that cause this bioavailability gap, quantitative absorption data from controlled studies, and the practical implications for research design when choosing delivery methods.